06 aug 25   physiomics plc - follow-on contract with uk biotech client physiomics plc | pyc | 0.5 0 0.0% | mkt cap: 1.39m    rns number : 0999u physiomics plc 06 august 2025   6 august 2025   physiomics plc ("physiomics" or the "company")   physiomics awarded follow-on contract with uk biotech client   physiomics plc (aim: pyc), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce the award of a second contract by a uk-based biotech client at the forefront of ai-driven drug development. this follows the successful completion of a previous project with the same client, which was announced in june 2024 and fell into the company's modelling and simulation division. under the new contract, physiomics will update a model previously developed for the client, incorporating clinical data from their ongoing phase 1 study. the updated model will be used to support critical decisions regarding future clinical dosing strategy. the project will leverage physiomics' proprietary virtual tumour™ platform and is expected to be completed over the next two months. the project is valued at approximately £38,000. dr peter sargent, ceo of physiomics, commented: "we're delighted to be working again with this valued client and to continue supporting the development of their oncology programme. this follow-on project provides a strong opportunity for our virtual tumour platform to help guide important clinical decisions and demonstrates the growing impact of model-informed approaches in dose optimisation decisions."    for more information about physiomics and its services, please visit www.physiomics.co.uk.   enquiries:   physiomics plc dr peter sargent, ceo +44 (0)1235 841575   hybridan llp (broker) claire louise noyce +44 (0) 203 764 2341   strand hanson ltd (nomad) james dance & james bellman +44 (0)20 7409 3494     notes to editor   about physiomics   physiomics plc combines expertise across modelling & simulation, biostatistics, data science and bioinformatics, together with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys. our approach is to help derive insight from all relevant and often disparate data in order to de-risk decision making and optimise research design across discovery, pre-clinical and clinical studies. through use of cutting-edge computational tools, bespoke models and our proprietary virtual tumour technology, the physiomics team has informed the development of over 100 commercial projects, with over 125 targets and drugs modelled. clients include merck kgaa, astellas, bicycle therapeutics, numab therapeutics & cruk.     this information is provided by rns, the news service of the london stock exchange. rns is approved by the financial conduct authority to act as a primary information provider in the united kingdom. terms and conditions relating to the use and distribution of this information may apply. for further information, please contact rns@lseg.com or visit www.rns.com.  rns may use your ip address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. for further information about how rns and the london stock exchange use the personal data you provide us, please see our privacy policy.   end   cnteelfbevlebbb return to news summary

Label: Gesunken